<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343638</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0130</org_study_id>
    <nct_id>NCT04343638</nct_id>
  </id_info>
  <brief_title>Effect of Intraoperative Nociception Control Based on Analgesia Nociception Index (ANI) Monitoring on Stress Response During Total Laparoscopic Hysterectomy</brief_title>
  <official_title>Effect of Intraoperative Nociception Control Based on Analgesia Nociception Index (ANI) Monitoring on Stress Response During Total Laparoscopic Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;Analgesia Nociception Index&quot; (ANI; MetroDoloris Medical Systems, Lille, France), derived
      from an electrocardiogram (ECG) trace, has been proposed as a noninvasive guide to analgesia.
      The ANI monitor calculates HR variation with respiration, a response mediated primarily by
      changes in the parasympathetic nervous system (PNS) stimulation to the sinoatrial node of the
      heart. The aim of this study is to determine the relation between ANI monitor values and
      serum catecholamine levels. We will compare the serum catecholamine (norepinephrine,
      epinephrine) levels of conventional nociception control group and ANI-monitor guided
      nociception control group at the end of surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The subject will be randomly allocated to 2 groups using computer-generated randomization method. Anesthesiologists will not be blinded to the groups because of organizational reasons.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum catecholamine (norepinephrine, epinephrine) level at the end of surgery</measure>
    <time_frame>at the end of surgery (skin closure)</time_frame>
    <description>Blood samples for serum catecholamine (norepinephrine, epinephrine) will be drawn at the end of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma inflammatory markers (IL-6, IL-10, HMGB1)</measure>
    <time_frame>1 hour after the end of surgery</time_frame>
    <description>Blood samples for plasma inflammatory markers (IL-6, IL-10, HMGB1) will be drawn 1 hour after the end of surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Patients Undergoing Total Laparoscopic Hysterectomy</condition>
  <arm_group>
    <arm_group_label>conventional nociception control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative opioid will be administered by conventional clinical practice. ANI monitor readings will not be visible to the anesthesiologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANI-monitor guided nociception control arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional nociception control</intervention_name>
    <description>While Intraoperative opioid will be administered by conventional clinical practice in control arm.</description>
    <arm_group_label>conventional nociception control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANI monitor guided nociception control</intervention_name>
    <description>The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.</description>
    <arm_group_label>ANI-monitor guided nociception control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. patients undergoing total laparoscopic hysterectomy under general anesthesia (American
        society of anesthesiologists classification 1~3)

        Exclusion Criteria:

          1. endometriosis

          2. AP diameter of uterus &gt; 12cm

          3. cognitive disorder

          4. arrhythmia, pacemaker

          5. chronic opioid use

          6. diseases affecting autoimmune system (immune disease, diabetic neuropathy)

          7. use of medications affecting ANI monitor (antimuscarinics, alpha-agonist, beta
             blocker)

          8. illiteracy, foreigner
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae Hoon Lee</last_name>
    <phone>82-10-2224-1055</phone>
    <email>neogens@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hoon Lee</last_name>
      <phone>82-10-2224-1055</phone>
      <email>neogens@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

